Full Press Release Details
Press Releases
Video Library
Careers
EAU 2025 BOND-003 COHORT P TRIAL IN PROGRESS
by
admin
Apr 3, 2025
congress-hub-presentations
CGON Positive Sentiment
EAU 2025 BOND-003 COHORT P TRIAL IN PROGRESS
Key Takeaway: The EAU 2025 BOND-003 Cohort P trial is currently underway, showcasing ongoing research efforts. This trial is part of a larger initiative presented at a significant congress event. The progress of this trial may contribute to advancements in the relevant field.
Price reaction · baseline $19.25 (2025-04-03T17:24:00.000Z) · hit during market hours · 2 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-2.6%
Market Sentiment Analysis
POSITIVE FACTORS
- The trial is currently in progress, indicating active research.
- The BOND-003 cohort is part of a significant congress event.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Frequently Asked Questions
What is the BOND-003 trial about?
The BOND-003 trial focuses on a specific cohort as part of ongoing research.
When is the EAU 2025 congress event?
The EAU 2025 congress event is scheduled for April 2025.
Who is conducting the BOND-003 trial?
The trial is being conducted by the organization associated with CGON.
What is the significance of the BOND-003 cohort?
The BOND-003 cohort is significant for its role in advancing research in its field.